Holen Sie sich die Stockscreener-App
19.84
3.98%
0.76
Handel nachbörslich:
19.84
Schlusskurs vom Vortag:
$19.08
Offen:
$19.08
24-Stunden-Volumen:
1.25M
Relative Volume:
0.70
Marktkapitalisierung:
$1.77B
Einnahmen:
$217.42M
Nettoeinkommen (Verlust:
$-243.25M
KGV:
-7.0979
EPS:
-2.7952
Netto-Cashflow:
$-278.35M
1W Leistung:
-2.75%
1M Leistung:
-17.78%
6M Leistung:
-3.13%
1J Leistung:
+34.69%
1-Tages-Spanne:
$18.82
$19.86
1-Wochen-Bereich:
$18.82
$20.71
52-Wochen-Spanne:
$12.99
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.84 | 1.77B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance
Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL.com
SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co. - marketbeat.com
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Syndax Pharmaceuticals (SNDX) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Net margin % of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Long term debt to total assets ratio of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Total common shares outstanding of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
State Street Corporation (SNDX) discloses 5.66M-share, 6.4% holding in Syndax - Stock Titan
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo Finance
Syndax Pharmaceuticals Inc (1T3) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
HC Wainwright Brokers Decrease Earnings Estimates for SNDX - marketbeat.com
Syndax Pharmaceuticals Inc (1T3) Q1 2024 Earnings ReportResults, Call & Slides - tipranks.com
Surging Revenue And Narrower Losses Might Change The Case For Investing In Syndax Pharmaceuticals (SNDX) - webull.com
What is HC Wainwright's Estimate for SNDX FY2029 Earnings? - marketbeat.com
Syndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses Persist - Sahm
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $26 to $57 - Moomoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Five New Syndax Employees Receive Stock Options With 4-Year Vesting - Stock Titan
Syndax Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-08-05 - Seeking Alpha
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $38.27, Implies 101% Upside - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings - MarketBeat
SNDX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus
HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - marketbeat.com
Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highli - GuruFocus
SNDX Q2 2026 Sales Surge Highlights Growth Potential Despite Val - GuruFocus
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ... - Yahoo! Finance Canada
Syndax Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
Syndax Pharmaceuticals (SNDX) Q2 Revenue Miss Highlights Valuati - GuruFocus
Is Syndax Pharmaceuticals Inc (SNDX) Facing Value Challenges Aft - GuruFocus
SNDX: Q2 revenue surged 92% year-over-year, driven by strong Revuforj and Niktimvo growth - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results - marketbeat.com
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
SNDX: Q2 2026 revenue jumped 92% YoY as losses narrowed and pipeline assets advanced - TradingView
Syndax: Q2 Earnings Snapshot - marketscreener.com
SNDX Financials: Income Statement, Balance Sheet & Cash Flow | Syndax Pharmaceuticals Inc - Stock Titan
Syndax Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update - finance.yahoo.com
Precision Trading with Syndax Pharmaceuticals Inc. (SNDX) Risk Zones - Stock Traders Daily
SNDX Stock Price, Quote & Chart - ChartMill
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):